Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 5/20 | 0.36 |
| ▸ | GHSR | Q92847 | 8/20 | 0.35 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.34 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6325620 | 0.86 | GHSR (0.37) | LTA4HGHSRITGB3ITGA2B | |
| SCHEMBL6319088 | 0.84 | LTA4H (0.35) | LTA4HGHSRCHRNB2CHRNA4 | |
| SCHEMBL6318942 | 0.84 | LTA4H (0.38) | LTA4HGHSRITGB3ITGA2B | |
| SCHEMBL6319863 | 0.82 | LTA4H (0.38) | LTA4HGHSRITGB3ITGA2B | |
| SCHEMBL6317890 | 0.81 | TACR1 (0.40) | LTA4HGHSR | |
| SCHEMBL7162631 | 0.80 | GHSR (0.37) | LTA4HGHSRITGB3ITGA2BCHRNB2 | |
| SCHEMBL6320627 | 0.79 | GHSR (0.34) | LTA4HGHSRCHRNB2CHRNA4 | |
| SCHEMBL6323200 | 0.79 | MMP3 (0.38) | LTA4HGHSR | |
| SCHEMBL6319052 | 0.79 | TACR1 (0.40) | LTA4HGHSR | |
| SCHEMBL6318755 | 0.79 | OPRM1 (0.34) | LTA4HGHSRCHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6939880-B2 | Compounds with growth hormone releasing properties | NOVO NORDISK A/S (DK) | 2005-09-06 | — | — | US | disclosed |
| US-20030055261-A1 | Compounds with growth hormone releasing properties | HELSINN THERAPEUTICS (U.S.), INC. | 2003-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055261-A1 | Compounds with growth hormone releasing properties | GHRHR, GHSR, IGFBP1 | LTA4H 3043/4885GHSR 2/4885ITGB3 4870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.